Sierra oncology, inc. (SRRA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-31,912

-47,462

-68,723

40,942

-13,032

-14,283

-62,537

35,010

-11,525

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-11,092

-

-15,209

-12,872

-10,538

-11,458

-18,505

-15,249

-8,048

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

180

Changes in fair value of warrant liabilities

16,240

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

7,487

8,630

1,326

Securities issuance obligation

1,485

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

918

958

1,280

1,758

1,699

1,694

1,821

1,782

1,499

1,407

1,460

1,511

1,527

1,545

1,299

1,303

1,363

-

-

-

-

Depreciation and amortization

55

-105

62

64

62

26

26

30

29

30

72

103

53

46

45

54

52

40

32

26

13

Other

-2

-262

97

-22

26

-99

-3

211

-41

-1

-13

18

-35

21

-14

-9

-13

-33

8

0

-9

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-429

-752

-655

68

1,003

-490

788

248

795

-368

1,179

-128

-568

-481

1,311

-553

85

393

498

425

-229

Accrued, other and operating lease liabilities

-1,522

311

-209

463

-2,599

1,678

399

1,954

-1,261

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-

-

-

309

814

870

-1,003

-8,897

7,776

859

-1,451

3,905

1,181

492

-276

Accounts payable

357

-299

106

583

-667

323

-159

385

-597

876

-58

-583

-1,452

2,430

-560

-1,039

1,415

-477

45

-1,143

1,581

Net cash used in operating activities

-13,948

-12,455

-11,106

-12,056

-15,566

-9,973

-14,265

-8,268

-12,609

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-11,364

-

-7,946

-10,322

-9,231

-7,076

-8,954

-7,249

-4,986

Purchase of property and equipment

-

6

14

5

14

-

-

-

-

0

5

9

78

18

3

14

179

33

127

242

12

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-25

0

0

100

50

Net cash used in investing activities

-

-6

-14

-5

-14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of common stock options

-

0

0

0

445

2

45

32

101

143

0

0

23

-

-

-

-

0

3

0

15

Purchase of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3

9

9

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-78

-

27

-1

-154

-33

9,901

-351

-71

Proceeds from issuance of common stock upon follow-on offering, net of offering costs

-

-

-

-

-

0

0

0

45,996

0

0

0

27,422

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

15

-

-

-

-

Net cash provided by financing activities

-

92,293

0

0

445

2

5,000

32

46,097

-

-

-

-

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

921

71

Proceeds from early exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

74

24

96

0

0

0

13

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

27,445

-

74

24

81

0

140,573

-654

-43

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-46

2

-17

-16

-3

-52

-3

-13

-20

-10

3

1

2

-

-

-

-

-

-

-

-

NET (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-13,994

79,834

-11,137

-12,077

-15,138

-10,082

-9,297

-8,279

33,468

-7,475

-8,875

-8,326

16,005

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-23

-22

-5

-

-

-

-

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,868

-10,321

-9,309

-7,128

141,508

-8,254

-5,100

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for (refund of) income taxes, net

14

26

-74

8

-29

0

-89

31

73

39

34

97

90

-

-

-

-

0

5

3

0

Cash paid for interest

-

90

83

82

81

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Issuance of common stock and common stock warrant in connection with an amendment to the asset purchase agreement

11,970

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of warrant liabilities to equity

62,175

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use asset obtained in exchange for operating lease obligation

-

0

0

0

771

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid property and equipment in accrued and other liabilities

12

-

-

-

-

-

-

-

21

-1

-5

3

7

75

-1

-9

20

-

-

-

-

Unpaid deferred financing costs in accrued and other liabilities

45

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs included in accrued and other liabilities

-

-

-

-

-

-

-

-

209

-

-

-

-

-

-

-

-

-

-

-

-

Change in redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-222,130

-140,880

-11,005

Offering costs included in accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

800

944